Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2005-08-12

Last Posted Date: 2016-06-01

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 62

Registration Number: NCT00129727

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Adenocarcinoma
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Malignant Pericardial Effusion
Malignant Pleural Effusion
Lung Adenosquamous Carcinoma
Minimally Invasive Lung Adenocarcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: Erlotinib
Drug: Carboplatin
Drug: Erlotinib Hydrochloride
Drug: Paclitaxel

First Posted Date: 2005-08-04

Last Posted Date: 2019-08-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 188

Registration Number: NCT00126581

Locations: 🇺🇸
University Medical Center of Southern Nevada, Las Vegas, Nevada, United States
🇺🇸
Kaiser Permanente-San Diego Mission, San Diego, California, United States
🇺🇸
Veterans Administration-San Diego Medical Center, San Diego, California, United States

and more 93 locations

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Biological: herceptin
Drug: carboplatin
Drug: docetaxel
Procedure: conventional surgery
Procedure: radiation therapy

First Posted Date: 2005-07-11

Last Posted Date: 2013-11-20

Lead Sponsor: University of Medicine and Dentistry of New Jersey

Target Recruit Count: 5

Registration Number: NCT00118053

Locations: 🇺🇸
Saint Peter's University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸
UMDNJ University Hospital, Newark, New Jersey, United States

and more 6 locations

Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Biological: cetuximab
Drug: carboplatin
Radiation: radiation therapy
Drug: pemetrexed disodium

First Posted Date: 2005-07-11

Last Posted Date: 2016-10-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 109

Registration Number: NCT00117962

Locations: 🇺🇸
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
🇺🇸
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, United States
🇺🇸
Missouri Cancer Associates, Columbia, Missouri, United States

and more 68 locations

A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood

Phase 2

Completed

Conditions: Lung Cancer
Ovarian Cancer
Breast Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: pegfilgrastim

First Posted Date: 2005-07-07

Last Posted Date: 2013-05-13

Lead Sponsor: Amgen

Target Recruit Count: 61

Registration Number: NCT00117442

Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Phase 1

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2005-06-14

Last Posted Date: 2009-11-26

Lead Sponsor: University of Virginia

Target Recruit Count: 48

Registration Number: NCT00114153

Locations: 🇺🇸
University of Virginia Cancer Center at UV Health System, Charlottesville, Virginia, United States

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: sunitinib

First Posted Date: 2005-06-09

Last Posted Date: 2010-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 84

Registration Number: NCT00113516

Locations: 🇫🇷
Pfizer Investigational Site, Villejuif, France

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer

Phase 2

Completed

Conditions: Sarcoma

Interventions: Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2005-06-03

Last Posted Date: 2018-09-25

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 55

Registration Number: NCT00112489

Locations: 🇺🇸
Fox Chase Cancer Center CCOP Research Base, Philadelphia, Pennsylvania, United States
🇺🇸
Mount Carmel Health - West Hospital, Columbus, Ohio, United States
🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 107 locations

Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2005-06-03

Last Posted Date: 2013-08-26

Lead Sponsor: University Hospital Birmingham

Target Recruit Count: 1350

Registration Number: NCT00112710

Locations: 🇬🇧
Institute of Clinical Research - Birmingham, Birmingham, England, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, England, United Kingdom

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small-Cell Lung Carcinoma

Interventions: Drug: Paclitaxel (Taxane)
Drug: Docetaxel (Taxane)
Drug: Carboplatin
Drug: Cetuximab

First Posted Date: 2005-06-02

Last Posted Date: 2015-12-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 755

Registration Number: NCT00112294

Locations: 🇺🇸
Local Institution, Madison, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy